Interms of Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we submit the Investor Presentation of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries filed its updated Investor Presentation with BSE on January 31, 2026. The presentation highlights strong FY25 results with revenue of Rs. 505 Cr (up 9% YoY), EBITDA jumping 75% to Rs. 39.9 Cr, and PAT growing 39% to Rs. 15.88 Cr. EBITDA margin expanded from 4.9% to 7.9%, and ROCE improved to 16% from 11.5%. Key strategic updates include proposed FCCB fundraise of USD 35 Million, acquisition of capex worth Rs. 25.50 Cr from Srigen Lifesciences, a new subsidiary in Singapore, and incorporation of Sudarshan Maven Pharma. The company is also manufacturing Vitamin B1 and B6 under the government PLI scheme and operates a Hyderabad unit for API intermediates.
The presentation showcases significant margin expansion and profitability growth, which is positive for shareholders. However, debt-to-equity rose sharply from 0.9x to 1.4x, and short-term borrowings increased substantially, reflecting funding for acquisitions and expansion that investors should monitor closely.